Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO Private Facebook Group
to join : go to
or contact
Ubiome Gut EXPLORER : 10% OFF
Join/Watch the weekly
TMAU UP Podcasts

Videos : TMAU stories

Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect

£ 943.03/GBP
$ 568.00/USD

TOTAL at today's ROE
£0.80/GBP = $1.00/USD

£1,398.07 = $1,745.14



Your currency will be automatically converted to USD or GBP by PayPal.

Option: pay with your credit card instead of PayPal account by clicking on either Donate button above.

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

Friday, February 4, 2011

New TMAU review paper by Dr Christodoulou

Trimethylaminuria papers published in medical journals are a rare occurrence. So it is nice to see a paper published recently, although it is only a review rather than new research. The review is by Dr John Christodoulou of the Genetic Metabolic Disorders Service, The Children's Hospital at Westmead and Disciplines of Paediatrics and Child Health and Genetic Medicine, Sydney Medical School, University of Sydney, Sydney, Australia.

Dr Christodoulou has a history in trimethylaminuria research. Indeed He authored the research proposal which was meticulously written that gave the community hope a couple of years ago, which was posted in the blog. Unfortunately funding did not materialize for the proposal.

Here is the pubmed information for Dr Christodoulou's new TMAU review paper below :

Trimethylaminuria: An under-recognised and socially debilitating metabolic disorder.
Christodoulou J.

Primary flavin mono-oxygenase 3 deficiency, an inborn error of choline metabolism, leads to an accumulation of trimethylamine, which because of its associated pungent odour of rotting fish, is a socially crippling disorder. Although it often has its onset in early childhood, it may take years or even decades before the diagnosis is established. In this review the clinical biochemical and genetic features of the disorder are reported. The principles of therapy will also be covered, including dietary, pharmacological approaches, as well as techniques used to manipulate the gastrointestinal environment as a strategy to reduce the gastrointestinal load of trimethylamine.

Dr Christodoulou abstract of TMAU review 2011

Dr Christodoulou, being a geneticist and pediatrician, is interested in all genetic disorders. Currently he is working on research for phenylketonuria that involves introducing a genetically engineered probiotic to the gut that is rich in the enzyme that metabolizes the compound present in the gut that PKU sufferers cannot metabolize. This idea has been suggested for TMAU too, and in principle may work for TMAU also, metabolizing the trimethylamine present in the gut.

At present, John and his team are also investigating genetically engineered probiotics as a treatment of human disease. One such disease, Phenylketonuria (PKU), is due to phenylalanine hydroxylase deficiency and, if untreated, results in profound intellectual disability, seizures and aggressive behaviour. Treatment consists of a life-long diet, restricting phenylalanine intake. The diet, however, is unpalatable, and for a number of reasons, compliance tends to deteriorate with age. A group led by John, in collaboration with Dr Ian Alexander of the Gene Therapy Research Unit, Dr Ted O’Loughlin of the Gastroenterology Research Unit (both at the Children’s Hospital at Westmead), and Professor Peter Pouwells of the TNO Nutrition and Food Research Institute in the Netherlands, is developing a novel therapy for treating PKU. This will involve genetically engineering harmless Lactobacillus bacteria to produce an alternate phenylalanine-metabolising enzyme, phenylalanine ammonia-lyase. These engineered organisms, if given orally (as a ‘Yakhult’ type preparation), should metabolise phenylalanine in the small intestine, preventing blood levels from rising. If successful, this novel form of treatment could be translated to other human diseases

Source : Dr John Christodoulou career biography


Post a Comment